<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856583</url>
  </required_header>
  <id_info>
    <org_study_id>99824</org_study_id>
    <secondary_id>2004-000213-19</secondary_id>
    <nct_id>NCT00856583</nct_id>
  </id_info>
  <brief_title>Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use</brief_title>
  <acronym>SCoP</acronym>
  <official_title>Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Croatia: Agency for Medicinal Product and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Greece: Ministry of Health and Welfare</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Latvia: State Agency of Medicines</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Luxembourg: Ministère de la Santé</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Philippines: Bureau of Food and Drugs</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Serbia and Montenegro: Agency for Drugs and Medicinal Devices</authority>
    <authority>Singapore: Clinical Trials &amp; Epidemiology Research Unit (CTERU)</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Taiwan: National Bureau of Controlled Drugs</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether there is an increased all-cause mortality
      in sertindole-treated patients in comparison to patients treated with a well-known
      antipsychotic (risperidone) when used under normal marketed conditions in the treatment of
      schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Committee for Medicinal Products for Human Use (CHMP) requested a post-marketing study
      to ascertain that the favourable benefit-risk profile and low mortality rates seen in the
      clinical studies with sertindole would not be offset by higher mortality rates when
      sertindole was used under more normal conditions of use. It was recognised that, in a
      clinical trial setting, strict patient selection and monitoring could lead to higher
      compliance in patient management and thereby to a lower mortality rate. Study 99824 was
      therefore designed in collaboration with the CHMP as an open-label, randomised study with
      minimum study management that focused on mortality and general patient safety. The duration
      of the treatment period was not fixed. No efficacy measures were included.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants With All-cause Mortality</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality: Number of Participants With Completed Suicides - ISC</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure</measure>
    <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9809</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Sertindole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normally in the range of 4 to 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normally in the range of 2 to 8 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertindole</intervention_name>
    <description>Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases</description>
    <arm_group_label>Sertindole</arm_group_label>
    <other_name>Serdolect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has signed the Informed Consent Form or, if he/she is not able to sign it
             (according to the ICH GCP guidelines and the Declaration of Helsinki), the patient's
             legal representative has signed the Informed Consent Form

          -  The patient has been diagnosed with schizophrenia

          -  Based on the patient's clinical status, new or change of antipsychotic treatment is
             indicated

          -  The patient is at least 18 years of age

          -  The patient meets the criteria set out in the national SPCs for sertindole and
             risperidone. For those countries in which sertindole was not marketed, the EU SPC
             applied

        Exclusion Criteria:

          -  The last treatment taken by the patient was sertindole or risperidone

          -  The patient has never previously received any antipsychotic drug therapy

          -  The patient has contraindications to treatment with either sertindole or risperidone

          -  In addition to sertindole/risperidone, treatment with another antipsychotic is
             indicated

          -  The patient is homeless

          -  The patient has previously been included in one of the two H. Lundbeck A/S
             post-marketing studies, 99823 or 99824

          -  The patient is, in the opinion of the investigator, unlikely to comply with the study
             protocol or unsuitable for any other reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <results_reference>
    <citation>Peuskens J, Tanghøj P, Mittoux A; Sertindole Cohort. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol Drug Saf. 2008 May;17(5):425-33. doi: 10.1002/pds.1594.</citation>
    <PMID>18384186</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghøj P, Toumi M, Moore ND, Mann RD. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010 Nov;122(5):345-55. doi: 10.1111/j.1600-0447.2010.01563.x.</citation>
    <PMID>20384598</PMID>
  </results_reference>
  <results_reference>
    <citation>Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, Hall GC, Le Jeunne C, Mittoux A, Peuskens J, Priori S, Sturkenboom M, Thomas SH, Tanghøj P, Toumi M, Mann R, Moore ND. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol. 2010 Dec;20(12):829-38. doi: 10.1016/j.euroneuro.2010.09.001.</citation>
    <PMID>20926264</PMID>
  </results_reference>
  <results_reference>
    <citation>De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci. 2011 Jun;261(4):231-9. doi: 10.1007/s00406-010-0142-x. Epub 2010 Sep 5.</citation>
    <PMID>20820795</PMID>
  </results_reference>
  <results_reference>
    <citation>De Hert M, Mittoux A, He Y, Peuskens J. A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophr Res. 2010 Nov;123(2-3):276-7. doi: 10.1016/j.schres.2010.07.030. Epub 2010 Aug 21.</citation>
    <PMID>20732794</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 18, 2011</lastchanged_date>
  <firstreceived_date>March 5, 2009</firstreceived_date>
  <firstreceived_results_date>May 4, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>H. Lundbeck A/S</name_title>
    <organization>H. Lundbeck A/S</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Sertindole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>593 centres in 38 countries (Europe and Asia). First patient first visit: 11 July 2002. Last patient last visit: 22 February 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sertindole</title>
          <description>Normally in the range of 4 to 20 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>Normally in the range of 2 to 8 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4905">Patients treated</participants>
                <participants group_id="P2" count="4904">Patients treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1768">Patients who were still on study drug at the time of study closure</participants>
                <participants group_id="P2" count="2307">Patients who were still on study drug at the time of study closure</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3137"/>
                <participants group_id="P2" count="2597"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="377"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event (SAE)</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-SAE: Mostly Asymptomatic ECGs</title>
              <participants_list>
                <participants group_id="P1" count="393"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="262"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1092"/>
                <participants group_id="P2" count="919"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-evaluable: Patient on Polytherapy</title>
              <participants_list>
                <participants group_id="P1" count="694"/>
                <participants group_id="P2" count="604"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertindole</title>
          <description>Normally in the range of 4 to 20 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>Normally in the range of 2 to 8 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4905"/>
                <measurement group_id="B2" value="4904"/>
                <measurement group_id="B3" value="9809"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.4" spread="11.8"/>
                <measurement group_id="B2" value="38.3" spread="11.7"/>
                <measurement group_id="B3" value="38.3" spread="11.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18 to 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4806"/>
                <measurement group_id="B2" value="4820"/>
                <measurement group_id="B3" value="9626"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
                <measurement group_id="B2" value="84"/>
                <measurement group_id="B3" value="183"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2195"/>
                <measurement group_id="B2" value="2188"/>
                <measurement group_id="B3" value="4383"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2710"/>
                <measurement group_id="B2" value="2716"/>
                <measurement group_id="B3" value="5426"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration of schizophrenia</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="125"/>
                <measurement group_id="B2" value="87"/>
                <measurement group_id="B3" value="212"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&lt; 5 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1450"/>
                <measurement group_id="B2" value="1468"/>
                <measurement group_id="B3" value="2918"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>5 to 10 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1254"/>
                <measurement group_id="B2" value="1278"/>
                <measurement group_id="B3" value="2532"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; 10 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2076"/>
                <measurement group_id="B2" value="2071"/>
                <measurement group_id="B3" value="4147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Reasons for prescription of study drug</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Adverse drug reaction</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1121"/>
                <measurement group_id="B2" value="1072"/>
                <measurement group_id="B3" value="2193"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Lack of efficacy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2542"/>
                <measurement group_id="B2" value="2580"/>
                <measurement group_id="B3" value="5122"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>None or poor compliance</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="161"/>
                <measurement group_id="B2" value="169"/>
                <measurement group_id="B3" value="330"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Patient's choice</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="992"/>
                <measurement group_id="B2" value="979"/>
                <measurement group_id="B3" value="1971"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
                <measurement group_id="B2" value="104"/>
                <measurement group_id="B3" value="193"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number of previous suicide attempts</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>0 previous suicide attempts</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4281"/>
                <measurement group_id="B2" value="4288"/>
                <measurement group_id="B3" value="8569"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>1 previous suicide attempt</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="378"/>
                <measurement group_id="B2" value="377"/>
                <measurement group_id="B3" value="755"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2 previous suicide attempts</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="125"/>
                <measurement group_id="B2" value="126"/>
                <measurement group_id="B3" value="251"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>3 previous suicide attempts</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="105"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>4 previous suicide attempts</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;= 5 previous suicide attempts</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Time since last suicide attempt</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>No previous suicide attempt or unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4298"/>
                <measurement group_id="B2" value="4301"/>
                <measurement group_id="B3" value="8599"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&lt; 1 year</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="122"/>
                <measurement group_id="B2" value="117"/>
                <measurement group_id="B3" value="239"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>1 to 5 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="226"/>
                <measurement group_id="B2" value="218"/>
                <measurement group_id="B3" value="444"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; 5 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="259"/>
                <measurement group_id="B2" value="268"/>
                <measurement group_id="B3" value="527"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All-cause Mortality</title>
        <description>The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population included all patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With All-cause Mortality</title>
            <description>The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Number of deaths (WRT+30 days)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of deaths (ORT)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of the first primary outcome was the null hypothesis of an excess mortality in sertindole-treated patients compared to the mortality in risperidone-treated patients for the WRT+30 days period.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>If the upper limit of the 90% confidence interval (CI) for the estimated all-cause mortality ratio was &lt;1.5 (pre-specified), the null hypothesis was rejected. With this limit, 7,600 patient years of exposure (PYE) were required to ensure 80% power at the 5% significance level of rejecting the null hypothesis when assuming a mortality of 2 deaths per 100 PYE. As the actual mortality was only about half that anticipated, more exposure was necessary and the duration of the study increased markedly.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, time since last suicide attempt, last previous antipsychotic treatment (mono-/polytherapy), year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.117</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>1.500</ci_upper_limit>
            <estimate_desc>The hazard ratio is calculated as sertindole (numerator) versus risperidone (denominator).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of the first primary outcome was the null hypothesis of an excess mortality in sertindole-treated patients compared to the mortality in risperidone-treated patients for the ORT period.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>If the upper limit of the 90% CI for the estimated all-cause mortality ratio was &lt;1.5 (pre-specified), the null hypothesis was rejected. With this limit, 7,600 PYE were required to ensure 80% power at the 5% significance level of rejecting the null hypothesis when assuming a mortality of 2 deaths per 100 PYE. As the actual mortality was only about half that anticipated, more exposure was necessary and the duration of the study increased markedly.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, time since last suicide attempt, last previous antipsychotic treatment (mono-/polytherapy), year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.980</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.684</ci_lower_limit>
            <ci_upper_limit>1.405</ci_upper_limit>
            <estimate_desc>The hazard ratio is calculated as sertindole (numerator) versus risperidone (denominator).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC</title>
        <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population included all patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC</title>
            <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of mortality hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0022</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted: age, sex, time since last suicide attempt, last previous antipsychotic treatment (mono-/polytherapy), region, year since start of enrollment</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>5.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation</title>
        <description>Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population included all patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation</title>
            <description>Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of time to 1st occurence of the secondary primary outcome (one patient in the risperidone group reported more than one occurrence of this event) was the null hypothesis of hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.29</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age and sex.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>4.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality: Number of Participants With Completed Suicides - ISC</title>
        <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cause-specific Mortality: Number of Participants With Completed Suicides - ISC</title>
            <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of mortality hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.34</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, time since last suicide attempt, last previous antipsychotic treatment (mono-/polytherapy), year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC</title>
        <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC</title>
            <description>The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of mortality hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.26</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, last previous antipsychotic treatment (mono-/polytherapy), year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.715</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA</title>
        <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA</title>
            <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of mortality hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.081</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, last previous antipsychotic treatment (mono-/polytherapy).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA</title>
        <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA</title>
            <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of mortality hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.24</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, time since last suicide attempt, last previous antipsychotic treatment (mono-/polytherapy), year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA</title>
        <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA</title>
            <description>The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of mortality hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.59</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, last previous antipsychotic treatment (mono-/polytherapy), year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC</title>
        <description>The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population included all patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC</title>
            <description>The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.
The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of time to 1st occurence of this secondary outcome was the null hypothesis of hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.65</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, duration of schizophrenia, time since last suicide attempt, year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA</title>
        <description>The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA</title>
            <description>The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of time to 1st occurence of this secondary outcome was the null hypothesis of hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.044</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, duration of schizophrenia, time since last suicide attempt, year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease</title>
        <description>The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population included all patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease</title>
            <description>The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="174"/>
                  <measurement group_id="O2" value="149"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of time to 1st occurence of this secondary outcome was the null hypothesis of hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.040</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted for: age, sex, time since last suicide attempt, last antipsychotic medication (a-/typicals/both), region, year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure</title>
        <description>The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study</description>
        <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population included all patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertindole</title>
            <description>Normally in the range of 4 to 20 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Normally in the range of 2 to 8 mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4905"/>
                  <measurement group_id="O2" value="4904"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure</title>
            <description>The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3136" spread="430 PET?"/>
                  <measurement group_id="O2" value="2597" spread="433"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The basis for the statistical analysis of this secondary outcome was the null hypothesis of hazard ratio equal to 1 for the sertindole-treated patients versus risperidone-treated patients during the WRT+30 days period.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Cox Proportional Hazard</method>
            <method_desc>Adjusted: disease duration, time since last suicide attempt, last antipsychotic medication (a-/typicals/both), region, year since start of enrollment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months.</time_frame>
      <desc>Data on all serious adverse events and non-serious cardiac adverse events were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sertindole</title>
          <description>Normally in the range of 4 to 20 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>Normally in the range of 2 to 8 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="4905"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperprolactinaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Meibomianitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hepatocellular damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Infection in an immunocompromised host</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Obstructive chronic bronchitis with acute exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="4905"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="4905"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose intentional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="4905"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Self mutilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Medical observation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Type 2 diabetis mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Osteoporosis postmenopausal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of testis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gammopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Scrotal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="4905"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4905"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="4905"/>
                <counts group_id="E2" events="49" subjects_affected="45" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Galactorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Haematosalpinx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Drug abuser</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Social problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Treatment noncompliance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Plastic surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4904"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4905"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="397" subjects_at_risk="4905"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="397" subjects_at_risk="4905"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4904"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the investigator will be subject to mutual agreement between the investigator and H. Lundbeck A/S.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
